Empagliflozin benefits in patients with heart failure and
preserved ejection fraction

J 2022

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

ANKER, Stefan D; Javed BUTLER; Muhammad Shariq USMAN; Gerasimos FILIPPATOS; João Pedro FERREIRA et al.

Základní údaje

Originální název

Empagliflozin benefits in patients with heart failure and preserved ejection fraction

Autoři

Vydání

NATURE MEDICINE, BERLIN, NATURE PORTFOLIO, 2022, 1078-8956

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 82.900

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00128843

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

empagliflozin in heart failure; versus mid-range ejection fraction

Štítky

14110115, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2024 09:38, Mgr. Tereza Miškechová

Anotace

V originále

The EMPEROR-Preserved trial showed that the sodium–glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41–49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71–0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66–1.04, P = 0.11). For patients with an LVEF of 41–49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57–0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42–0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.

Citovat

ANKER, Stefan D; Javed BUTLER; Muhammad Shariq USMAN; Gerasimos FILIPPATOS; João Pedro FERREIRA; Edimar BOCCHI; Michael BÖHM; Hans Pieter Brunner-La ROCCA; Choi DONG-JU; Vijay CHOPRA; Eduardo CHUQUIURE; Nadia GIANNETTI; Juan Esteban GOMEZ-MESA; Stefan JANSSENS; James L JANUZZI; José R GONZÁLEZ-JUANATEY; Bela MERKELY; Stephen J NICHOLLS; Sergio V PERRONE; Ileana L PIÑA; Piotr PONIKOWSKI; Michele SENNI; David SIM; Jindřich ŠPINAR; Iain SQUIRE; Stefano TADDEI; Hiroyuki TSUTSUI; Subodh VERMA; Dragos VINEREANU; Jian ZHANG; Tomoko IWATA; Janet M SCHNEE; Martina BRUECKMANN; Stuart J POCOCK a Faiez ZANNAD. Empagliflozin benefits in patients with heart failure and preserved ejection fraction. NATURE MEDICINE. BERLIN: NATURE PORTFOLIO, 2022, roč. 28, č. 12, s. "2512"-"+", 18 s. ISSN 1078-8956. Dostupné z: https://doi.org/10.1038/s41591-022-02041-5.

@article{2266097,
   author = {Anker, Stefan D and Butler, Javed and Usman, Muhammad Shariq and Filippatos, Gerasimos and Ferreira, João Pedro and Bocchi, Edimar and Böhm, Michael and Rocca, Hans Pieter BrunnerandLa and DongandJu, Choi and Chopra, Vijay and Chuquiure, Eduardo and Giannetti, Nadia and GomezandMesa, Juan Esteban and Janssens, Stefan and Januzzi, James L and GonzálezandJuanatey, José R and Merkely, Bela and Nicholls, Stephen J and Perrone, Sergio V and Piña, Ileana L and Ponikowski, Piotr and Senni, Michele and Sim, David and Špinar, Jindřich and Squire, Iain and Taddei, Stefano and Tsutsui, Hiroyuki and Verma, Subodh and Vinereanu, Dragos and Zhang, Jian and Iwata, Tomoko and Schnee, Janet M and Brueckmann, Martina and Pocock, Stuart J and Zannad, Faiez},
   article_location = {BERLIN},
   article_number = {12},
   doi = {https://doi.org/10.1038/s41591-022-02041-5},
   keywords = {empagliflozin in heart failure; versus mid-range ejection fraction},
   language = {eng},
   issn = {1078-8956},
   journal = {NATURE MEDICINE},
   title = {Empagliflozin benefits in patients with heart failure and preserved ejection fraction},
   url = {https://www.nature.com/articles/s41591-022-02041-5},
   volume = {28},
   year = {2022}
}

TY  - JOUR
ID  - 2266097
AU  - Anker, Stefan D - Butler, Javed - Usman, Muhammad Shariq - Filippatos, Gerasimos - Ferreira, João Pedro - Bocchi, Edimar - Böhm, Michael - Rocca, Hans Pieter Brunner-La - Dong-Ju, Choi - Chopra, Vijay - Chuquiure, Eduardo - Giannetti, Nadia - Gomez-Mesa, Juan Esteban - Janssens, Stefan - Januzzi, James L - González-Juanatey, José R - Merkely, Bela - Nicholls, Stephen J - Perrone, Sergio V - Piña, Ileana L - Ponikowski, Piotr - Senni, Michele - Sim, David - Špinar, Jindřich - Squire, Iain - Taddei, Stefano - Tsutsui, Hiroyuki - Verma, Subodh - Vinereanu, Dragos - Zhang, Jian - Iwata, Tomoko - Schnee, Janet M - Brueckmann, Martina - Pocock, Stuart J - Zannad, Faiez
PY  - 2022
TI  - Empagliflozin benefits in patients with heart failure and preserved ejection fraction
JF  - NATURE MEDICINE
VL  - 28
IS  - 12
SP  - "2512"-"+"
EP  - "2512"-"+"
PB  - NATURE PORTFOLIO
SN  - 10788956
KW  - empagliflozin in heart failure
KW  - versus mid-range ejection fraction
UR  - https://www.nature.com/articles/s41591-022-02041-5
N2  - The EMPEROR-Preserved trial showed that the sodium–glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41–49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71–0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66–1.04, P = 0.11). For patients with an LVEF of 41–49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57–0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42–0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.
ER  -

ANKER, Stefan D; Javed BUTLER; Muhammad Shariq USMAN; Gerasimos FILIPPATOS; João Pedro FERREIRA; Edimar BOCCHI; Michael BÖHM; Hans Pieter Brunner-La ROCCA; Choi DONG-JU; Vijay CHOPRA; Eduardo CHUQUIURE; Nadia GIANNETTI; Juan Esteban GOMEZ-MESA; Stefan JANSSENS; James L JANUZZI; José R GONZÁLEZ-JUANATEY; Bela MERKELY; Stephen J NICHOLLS; Sergio V PERRONE; Ileana L PIÑA; Piotr PONIKOWSKI; Michele SENNI; David SIM; Jindřich ŠPINAR; Iain SQUIRE; Stefano TADDEI; Hiroyuki TSUTSUI; Subodh VERMA; Dragos VINEREANU; Jian ZHANG; Tomoko IWATA; Janet M SCHNEE; Martina BRUECKMANN; Stuart J POCOCK a Faiez ZANNAD. Empagliflozin benefits in patients with heart failure and preserved ejection fraction. \textit{NATURE MEDICINE}. BERLIN: NATURE PORTFOLIO, 2022, roč.~28, č.~12, s.~''2512''-''+'', 18 s. ISSN~1078-8956. Dostupné z: https://doi.org/10.1038/s41591-022-02041-5.

Přehled o publikaci